Interventional cardiologist @umichCVC: Low-risk approval for #TAVR is a "momentous event" that's "completely transformed the way we treat people with aortic stenosis"


Expert Pitch
  • newswise-fullscreen Interventional cardiologist @umichCVC: Low-risk approval for #TAVR is a

    Credit: Michigan Medicine

    Stanley Chetcuti, M.D., of the University of Michigan, comments on the new FDA approval of TAVR for low-risk patients.

"Today is a momentous event that crowns an epic journey that has completely transformed the way we treat people with aortic stenosis.

People now have all options available and it gives us all an immense responsibility to ensure that we can deliver it to them in the safest way and with the best outcomes.

We are also entrusted with the responsibility to ensure that the technology is not abused, and to follow patients for a long time to ensure that the long term outcomes are just as good."

- Stanley J Chetcuti, M.D.

Interventional cardiologist at Michigan Medicine's (University of Michigan) Frankel Cardiovascular Center

 

Director, Cardiac Catheterization Laboratory

Co-author on EVOLUT trial

 

*Feel free to use above quote or contact for interview with a specialist at Michigan Medicine's Frankel Cardiovascular Center

  • share-facebook-Interventional cardiologist @umichCVC: Low-risk approval for #TAVR is a
  • share-twitter-Interventional cardiologist @umichCVC: Low-risk approval for #TAVR is a

Comment/Share

Chat now!